Opioid crisis sparks leadership changes at Purdue Pharma
In an attempt to distance itself from the opioid epedemic, Purdue Pharma recently made some leadership changes to its board of directors and executive committee, as it battles hundreds of lawsuits across the United States concerning opioid-related deceptive sales and marketing practices that are the focus of U.S. enforcement authorities.
Related articles
-
ArticlePractice Fusion to overhaul compliance after $145M kickback resolution
Practice Fusion will pay a total of $145 million to resolve criminal and civil investigations for its leading role in an opioid kickback scheme. Particularly notable are the new compliance obligations imposed upon it, which are as weighty and significant as the fine itself.
-
Article
Chief compliance officer liability and the opioid epidemic
In a period of three months, two chief compliance officers have been charged for their individual roles in the opioid epidemic—a clear indication the Department of Justice continues to expand the scope of prosecutions to those who fail in their compliance responsibilities.
-
News BriefCommunication and relationships is increasingly critical for compliance teams
Compliance is increasingly in the spotlight as companies are tackling everything from artificial intelligence and other new technologies to risk management and mitigation. But it’s soft skills of communication and relationship building that are becoming the most critical tools for success.